Antiretroviral drug content in products from developing countries

Clinical Infectious Diseases

Volumn 38, Issue 9, 2004, Pages 1317-1319

  Penzak, Scott R ^a,d   Acosta, Edward P ^a   Turner, Michele ^a   Tavel, Jorge A ^b   Masur, Henry ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; GENERIC DRUG;

ARTICLE; CALIBRATION; DEVELOPING COUNTRY; DRUG CAPSULE; DRUG FORMULATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TABLET FORMULATION; BIOAVAILABILITY; CHEMISTRY; DRUG INDUSTRY; HUMAN; PHARMACOKINETICS;

ANTI-RETROVIRAL AGENTS; BIOLOGICAL AVAILABILITY; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, GENERIC; HUMANS; THERAPEUTIC EQUIVALENCY;

EID: 2342597713     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383575     Document Type: Article

References (11)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. UNAIDS Fact Sheet. Access to HIV Treatment and Care. September 2003. Available at: http://www.unaids.org/html/pub/Publications/Fact-Sheets03/ FS_Care_2003_en_doc.htm. Accessed 29 September 2003.
3. World Health Organization. World Health Organization says failure to deliver AIDS medicines is a global health emergency: global AIDS treatment emergency requires urgent response; no more business as usual. 22 September 2003. http://who.int/mediacentre/releases/2003/ pr67/en/index.html. Accessed 29 September 2003.
4. Gogtay JA, Manek V, Nayak VG, et al. A pharmacokinetic evaluation of lamivudine, stavudine, and nevirapine given as a fixed dose combination pill versus the same three drugs given separately in healthy human volunteers [abstract PL8.4]. In: Abstracts of the Sixth International Congress on Drug Therapy in HIV (Glasgow). Congress on HIV Infection, the Gardner Coldwell Group, part of the Thomson Corporation. Chesire, UK, 2002:11.
5. Kumarasamy N, Soloman S, Chaguturu SK, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003; 17:2267-9.
6. Penzak SR, Acosta EP, Turner M, Tavel JA, Masur H. Analysis of generic nevirapine products in developing countries. JAMA 2003; 289:2648-9.
7. Apoola A, Sriskandabalan PS, Wade AAH. Self medication with zidovudine that was not. Lancet 2001; 357:1370.
8. Newton PN, White NJ, Rozendaal JA, Green MD. Murder by fake drugs. BMJ 2002; 324:800-1.
9. United States Pharnmacopeia/National Formulary. Uniformity of dosage units. Rockville, MD: United States Pharmacopeial Convention, 2003:2227-9.
10. United States Pharnmacopeia/National Formulary. Uniformity of dosage units. Rockville, MD: United States Pharmacopeial Convention, 2003:1665.
11. Tribut O, Arvieux C, Michelet C, Chapplain JM, Allain H, Bentue-Ferrer D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nudeoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit 2002; 24:554-62.